Market Overview

Cyclacel Comments on Key Business Objectives for 2013

Related CYCC
Events Scheduled for Week of Jun 23rd to Jun 27th, 2014
Morning Market Losers

Cyclacel Pharmaceuticals (NASDAQ: CYCC) (NASDAQ: CYCCP) today reviewed 2012 achievements and provided an outline of the Company's key clinical development objectives for 2013, which will be highlighted at the Company's presentation during the Biotech Showcase™ 2013 Conference at 3:15 pm Pacific Time on Monday, January 7, 2013, at the Parc 55 Wyndham Hotel in San Francisco, CA.

"During 2012, we advanced the clinical development of sapacitabine in multiple indications. For example, in our SEAMLESS, Phase 3, registration-directed study, of sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (AML), our lead indication, we exceeded 100 patients enrolled with 37 trial sites open," said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. "In addition, the independent committee overseeing SEAMLESS recently recommended that the study should continue as planned and identified no safety or efficacy concerns. We are encouraged by the continued investigator interest in SEAMLESS and plan to open additional sites during 2013. Updated survival

See full press release

Posted-In: News Guidance Management Global

 

Most Popular

Related Articles (CYCC + CYCCP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters